Brokerages have turned bullish over Biocon's growth prospects after the US FDA clearance of the drugmaker's Malaysia unit ...

HSBC expects an operational turnaround for Biocon, driven by major biosimilar launches and a rebound in generics sales. The ...

The investigational new drug application for the nanoparticle drug SNB-101 has been cleared for small cell lung cancer ...

Biocon Ltd shares rose 4.7% after HSBC upgraded its rating to "buy" and raised the target price to Rs 430. The upgrade ...

HSBC's base case target suggests 10 per cent upside over the prevailing stock price. Its bull case target suggests 40 per ...

The stock has gained 9.66% in the last month, 7.99% over the past six months, and an impressive 37.98% in the last year.